Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

Exclusion Criteria

• •Ongoing prednisone requirement \> 1mg/kg/day (or equivalent)
• •Exposure to any new immunosuppressive medication in the 4 weeks prior to enrollment
• •Concurrent ECP therapy within 4 weeks prior to enrollment
• •Post-transplant exposure to any novel immunosuppressive medication within 100 days prior to enrollment
• •Donor lymphocyte infusion within 100 days prior to IL-2 therapy
• •Active malignant disease relapse
• •Active, uncontrolled infection
• •Positive serologic test for Hepatitis B or a positive serologic or nucleic acid test for Hepatitis C
• •HIV seropositivity
• •Life expectancy \< 3 months
• •Pregnancy or lactation
• •Inability to comply with IL-2 treatment regimen
• •Uncontrolled cardiac angina or symptomatic congestive heart failure
• •Organ transplant (allograft) recipient